Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Reimportation Revived? Or an Issue about to Expire?

This article was originally published in RPM Report

Executive Summary

Support for reimportation of lower-priced drugs from outside the US has been a rallying point for Democratic critics of the drug industry for almost a decade. But there are signs that some influential Democrats now view it as a distraction from the real target-cutting drug costs here.

You may also be interested in...



Pharma Must "Continue to Take Chances" In Policy World: Merck VP's Parting Advice

A conversation with Merck VP-global public policy Ian Spatz about the challenges and opportunities facing industry amid the changes in Washington.

Running Away from Part D: No Love for New Rx Benefit on Campaign Trail

It's no surprise that the Democratic Presidential candidates are attacking Medicare Part D. But the really bad news for Big Pharma is that the Republicans don't have anything nice to say about it either. At least for now.

Running Away from Part D: No Love for New Rx Benefit on Campaign Trail

It's no surprise that the Democratic Presidential candidates are attacking Medicare Part D. But the really bad news for Big Pharma is that the Republicans don't have anything nice to say about it either. At least for now.

Related Content

Topics

UsernamePublicRestriction

Register

LL009864

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel